Tracon Pharmaceuticals said today it has licensed two preclinical oncology candidates from Johnson & Johnson’s Janssen Pharmaceutica, which will retain rights to potentially reacquire the programs.
TRACON Pharmaceuticals (NASDAQ: TCON) has announced interim results from their Phase II ENVASARC pivotal trial of envafolimab, expressing confidence in the drug's potential during their Q4 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results